The JAK2 V617F mutation identified in 95% of PV patients and around 50% of ET and PMF cases acts as a driver for clonal proliferation through constitutive activation of the JAK/STAT pathway [1]. The gene discussed is JAK2; the disease is essential thrombocythemia.